ATE549320T1 - Neue zubereitung für die äusserliche anwendung - Google Patents

Neue zubereitung für die äusserliche anwendung

Info

Publication number
ATE549320T1
ATE549320T1 AT08827867T AT08827867T ATE549320T1 AT E549320 T1 ATE549320 T1 AT E549320T1 AT 08827867 T AT08827867 T AT 08827867T AT 08827867 T AT08827867 T AT 08827867T AT E549320 T1 ATE549320 T1 AT E549320T1
Authority
AT
Austria
Prior art keywords
external use
hydrate
salt
optionally substituted
formula
Prior art date
Application number
AT08827867T
Other languages
English (en)
Inventor
Chiharu Kimura
Maho Sakurai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE549320T1 publication Critical patent/ATE549320T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AT08827867T 2007-08-17 2008-08-15 Neue zubereitung für die äusserliche anwendung ATE549320T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007212926 2007-08-17
PCT/JP2008/064621 WO2009025239A1 (ja) 2007-08-17 2008-08-15 新規外用剤

Publications (1)

Publication Number Publication Date
ATE549320T1 true ATE549320T1 (de) 2012-03-15

Family

ID=40378144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08827867T ATE549320T1 (de) 2007-08-17 2008-08-15 Neue zubereitung für die äusserliche anwendung

Country Status (10)

Country Link
US (1) US8513269B2 (de)
EP (1) EP2202229B1 (de)
JP (1) JP5060561B2 (de)
KR (1) KR20100042246A (de)
CN (1) CN101687819B (de)
AT (1) ATE549320T1 (de)
AU (1) AU2008290001B2 (de)
CA (1) CA2696793A1 (de)
TW (1) TWI414296B (de)
WO (1) WO2009025239A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530654B2 (en) 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
ATE538102T1 (de) 2007-08-17 2012-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung eines chinazolinderivats
EP2751079A1 (de) * 2011-08-31 2014-07-09 Amakem NV Biphenylcarbonsäureamide als rock-kinasehemmer
WO2013054809A1 (ja) * 2011-10-14 2013-04-18 大正製薬株式会社 皮膚外用剤
JP2013147442A (ja) * 2012-01-18 2013-08-01 Kose Corp グリチルレチン酸ステアリルの皮膚浸透促進剤
WO2014133020A1 (ja) * 2013-02-28 2014-09-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 呼吸器疾患の予防治療剤
RU2768826C2 (ru) 2016-06-07 2022-03-24 Дермавант Саенсиз Гмбх Составы на основе ингибиторов pde-4 для местного применения и способы их применения
EP3714887A4 (de) * 2017-11-20 2021-08-11 Jiangsu Hengrui Medicine Co. Ltd. Pharmazeutische zusammensetzung zur topischen verabreichung und herstellungsverfahren dafür
WO2019113475A1 (en) * 2017-12-07 2019-06-13 Dermavant Sciences GmbH Topical ointment formulations and their use in treating skin conditions
KR20200097297A (ko) * 2017-12-07 2020-08-18 더마반트 사이언시즈 게엠베하 Pde-4 억제제의 국소 연고 제형 및 피부 병태 치료에서의 이의 용도
BR112021002656A2 (pt) * 2018-08-16 2021-05-11 Dr. Reddy's Laboratories Limited composições oleaginosas tópicas
WO2021262956A1 (en) * 2020-06-24 2021-12-30 Roivant Sciences Gmbh Topical gel formulations and their use in treating skin conditions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2099112T3 (es) 1990-09-04 1997-05-16 Fujisawa Pharmaceutical Co Pomadas que contienen un compuesto triciclico.
JP3466305B2 (ja) 1994-12-12 2003-11-10 久光製薬株式会社 溶解剤および該溶解剤を含有する外用製剤
WO1998010767A2 (en) * 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
JP3373838B2 (ja) 1999-10-25 2003-02-04 山之内製薬株式会社 ナフチリジン誘導体
AR029185A1 (es) 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
US20060084684A1 (en) 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
JP4387717B2 (ja) 2003-07-11 2009-12-24 株式会社資生堂 油中水型皮膚外用医薬品製剤
JP2005047909A (ja) 2003-07-17 2005-02-24 Santen Pharmaceut Co Ltd ピペリジン誘導体を有効成分とする掻痒治療剤
EP1647274A4 (de) 2003-07-17 2008-12-10 Ono Pharmaceutical Co Mittel zur behandlung von pruritus mit einem piperidin-derivat als wirkstoff
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2008137892A (ja) 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
WO2007097317A1 (ja) 2006-02-21 2007-08-30 Eisai R & D Management Co., Ltd. ４－（３－ベンゾイルアミノフェニル）－６，７－ジメトキシ－２－メチルアミノキナゾリン誘導体
TWI404709B (zh) 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
US8530654B2 (en) * 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
CA2678477A1 (en) 2007-02-16 2008-08-21 Eisai R&D Management Co., Ltd. Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid

Also Published As

Publication number Publication date
JP5060561B2 (ja) 2012-10-31
AU2008290001A1 (en) 2009-02-26
TWI414296B (zh) 2013-11-11
JPWO2009025239A1 (ja) 2010-11-25
TW200922589A (en) 2009-06-01
EP2202229B1 (de) 2012-03-14
CN101687819B (zh) 2013-03-20
CN101687819A (zh) 2010-03-31
EP2202229A4 (de) 2010-09-08
US20110021545A1 (en) 2011-01-27
WO2009025239A1 (ja) 2009-02-26
EP2202229A1 (de) 2010-06-30
KR20100042246A (ko) 2010-04-23
AU2008290001B2 (en) 2012-08-09
CA2696793A1 (en) 2009-02-26
US8513269B2 (en) 2013-08-20

Similar Documents

Publication Publication Date Title
EP2202229A4 (de) Neue zubereitung für die äusserliche anwendung
SMAP201100019A (it) Composti organici.
DK2020996T3 (da) Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
DK2074120T3 (da) Tropan-forbindelser
BRPI1009637A2 (pt) composto, composição e uso de um composto
BR112014003597A2 (pt) composto da fórmula i, processo de preparação de compostos da fórmula i, composto da fórmula xii, composto das fórmulas viii e xi, composição agroquímica, uso de compostos da fórmula i ou viii e semente revestida com pelo menos um composto da fórmula i ou viii
UY31831A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
AR083234A1 (es) Composicion pesticida y su uso
UY28967A1 (es) (orto-fenil)-anilidas de ácido 1-metil-3-difluorometil-pirazol-4-carboxílico y su uso como fungicida
BR112014007078A2 (pt) composição de controle de doença de plantas e seu uso
BR112014004268A2 (pt) método para a produção de agente de controle de praga
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
UA106880C2 (uk) Нові гербіциди
NZ716598A (en) Anthelmintic compounds and compositions and method of using thereof
PE20080949A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen
ATE548019T1 (de) Hautaufhellende mittel, zusammensetzungen und verfahren
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
EA201000604A1 (ru) Новые производные имидазола
BRPI0907052B8 (pt) processo para a preparação de compostos
AR067534A1 (es) Proceso para la preparacion de trifluoroalquil - fenil sulfonamidas y de sulfonamidas heterociclicas
WO2008113450A3 (de) Verwendung von chroman-4-on-derivaten
BRPI0800753A2 (pt) composiÇÕes contendo retinàide e derivados do Ácido beta-aminoisobutÍrico
DE602006006016D1 (de) Herstellung von Epoxidhärter enthaltenden wässrigen Zusammensetzungen
ECSP088170A (es) Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano, su preparación y su aplicación en terapéutica
BR112012013723A2 (pt) "uso de pelo menos um composto de fórmula (i), método para conservar uma composição cosmética, dermatológica ou farmacêutica e composição cosmética, dermatológica ou farmacêutica"